Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Cellerino

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Frontiers in Neurology|March 27, 2023
Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbiditiesCaterina Lapucci, Francesco Tazza, Silvia Rebella, et al.
Cornea|August 1, 2020
Neuroaxonal Degeneration in Patients With Multiple Sclerosis: An Optical Coherence Tomography and in Vivo Corneal Confocal Microscopy StudyValeria Testa, Nicole De Santis, Riccardo Scotto, et al.
Headache|January 21, 2025
The "central vein sign" to differentiate multiple sclerosis from migraineGiulia Silvestri, Luca Roccatagliata, Francesco Tazza, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 23, 2020
Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy studyValeria Testa, Nicole De Santis, Riccardo Scotto, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 16, 2019
Different MRI patterns in MS worsening after stopping fingolimodCaterina Lapucci, Damiano Baroncini, Maria Cellerino, et al.
Journal of Neurology|June 17, 2021
What happens after fingolimod discontinuation? A multicentre real-life experienceDoriana Landi, Alessio Signori, Maria Cellerino, et al.
Therapeutic Advances in Neurological Disorders|March 5, 2026
Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practiceAurora Zanghì, Giovanna Borriello, Matteo Foschi, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 23, 2021
Predictors of Ocrelizumab Effectiveness in Patients with Multiple SclerosisMaria Cellerino, Giacomo Boffa, Caterina Lapucci, et al.
Journal of Neurology|May 4, 2024
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched studyAurora Zanghì, Giovanna Borriello, Simona Bonavita, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Frontiers in Neurology|March 27, 2023
Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbiditiesCaterina Lapucci, Francesco Tazza, Silvia Rebella, et al.
Cornea|August 1, 2020
Neuroaxonal Degeneration in Patients With Multiple Sclerosis: An Optical Coherence Tomography and in Vivo Corneal Confocal Microscopy StudyValeria Testa, Nicole De Santis, Riccardo Scotto, et al.
Headache|January 21, 2025
The "central vein sign" to differentiate multiple sclerosis from migraineGiulia Silvestri, Luca Roccatagliata, Francesco Tazza, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 23, 2020
Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy studyValeria Testa, Nicole De Santis, Riccardo Scotto, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 16, 2019
Different MRI patterns in MS worsening after stopping fingolimodCaterina Lapucci, Damiano Baroncini, Maria Cellerino, et al.
Journal of Neurology|June 17, 2021
What happens after fingolimod discontinuation? A multicentre real-life experienceDoriana Landi, Alessio Signori, Maria Cellerino, et al.
Therapeutic Advances in Neurological Disorders|March 5, 2026
Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practiceAurora Zanghì, Giovanna Borriello, Matteo Foschi, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 23, 2021
Predictors of Ocrelizumab Effectiveness in Patients with Multiple SclerosisMaria Cellerino, Giacomo Boffa, Caterina Lapucci, et al.
Journal of Neurology|May 4, 2024
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched studyAurora Zanghì, Giovanna Borriello, Simona Bonavita, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.
Pageof 7